By Fineline Cube Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics, Inc., including an exclusive global license agreement for HS-20118 (AVR-001) and a significant equity stake in Avere’s all-stock merger with NextCure, Inc. (NASDAQ: NXTC). The combined transactions position Hansoh to capture substantial value from its cyclic peptide IL-23 receptor antagonist while securing a strategic foothold in the merged public entity.
Transaction Structure & Financial Terms
| Component | Detail |
|---|---|
| License Agreement | Exclusive global rights to HS-20118 excluding Greater China |
| Upfront Payment | USD 120 million |
| Milestone Payments | Up to USD 2.18 billion (development and sales-related) |
| Royalties | Mid-single to low-double-digit percentage on net sales |
| Equity Stake | 30-40% of combined entity on fully diluted basis |
| Territory Excluded | Mainland China, Hong Kong, Macau, Taiwan |
Asset Profile & Development Strategy
- Molecule: HS-20118 (AVR-001) – cyclic peptide IL-23 receptor antagonist
- Indication Focus: Oral therapies for IL-23-driven inflammatory diseases
- Development Stage: Preclinical/early clinical (specific stage not disclosed)
- Portfolio Company: Avere Therapeutics established as Hansoh Pharma spin-out focused on IL-23 pathway
Merger Integration – Public Market Acceleration
| Entity | Contribution | Strategic Rationale |
|---|---|---|
| Avere Therapeutics | Differentiated oral IL-23 program (HS-20118) | Novel mechanism addressing inflammatory disease market |
| NextCure, Inc. | Public listing structure (Nasdaq: NXTC) | Accelerated development timeline through public market access |
| Combined Entity | Avere Therapeutics, Inc. (ticker: AVRX) | Enhanced capital access and development resources |
| Transaction Timeline | Expected close in H2 2026 | Rapid execution to capitalize on IL-23 market opportunity |
The merger creates a publicly traded entity with a differentiated oral IL-23 antagonist positioned to compete in the $20B+ inflammatory disease market dominated by biologic therapies.
Market Impact & Strategic Positioning
- IL-23 Inhibitor Market: Oral IL-23 antagonists represent a significant advancement over injectable biologics, offering improved patient convenience and compliance
- Competitive Edge: Cyclic peptide approach may provide superior selectivity and safety profile compared to monoclonal antibody competitors
- Strategic Value Creation: Hansoh retains Greater China rights while monetizing global potential through upfront payments, milestones, royalties, and equity appreciation
- Financial Upside: Total potential deal value of $2.3B plus equity stake in publicly traded entity creates multiple value realization pathways
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the license agreement, merger transaction, and clinical development of HS-20118. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, merger completion, and competitive dynamics.-Fineline Info & Tech